Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.
Arcturus Therapeutics Holdings Inc. reports developments as a commercial messenger RNA medicines and vaccines company focused on liver and respiratory rare disease therapeutics and infectious disease vaccines. Its news commonly covers pipeline progress for cystic fibrosis and ornithine transcarbamylase deficiency programs, including LUNAR-CF, ARCT-032, LUNAR-OTC and ARCT-810, as well as updates tied to its LUNAR lipid-mediated delivery and STARR self-amplifying mRNA technologies.
Company updates also address KOSTAIVE COVID-19 vaccine activity, partnered vaccine programs with CSL Seqirus, the ARCALIS manufacturing joint venture in Japan, collaboration revenue, research and development spending, quarterly financial results, investor conference participation, and executive or board changes.
Summary not available.
Summary not available.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced it will release its financial results for the quarter ended March 31, 2023, after the market close on May 9, 2023. The Company, focused on mRNA medicines for infectious disease vaccines and rare diseases, will also host a conference call and webcast at 4:30 PM ET on the same day. Established in 2013 and based in San Diego, Arcturus utilizes innovative delivery technologies like LUNAR® and STARR™ mRNA Technology. Its pipeline includes candidates for treating ornithine transcarbamylase deficiency and cystic fibrosis, alongside partners in mRNA vaccine programs for COVID-19 and influenza. For more details, visit www.ArcturusRx.com.
Arcturus Therapeutics Holdings announced significant financial results for Q4 2022, highlighting a revenue surge to $160.3 million, driven by a $200 million payment from CSL collaboration. The company achieved $90 million in development milestones in March 2023, bolstering its cash runway into 2026. ARCT-154 Phase 3 trial for COVID-19 booster is fully enrolled in Japan, with ARCT-810 and ARCT-032 advancing in clinical trials. The company reported a net income of $117.3 million for Q4, compared to a loss the previous year. Cash balance was $391.9 million at year-end, reflecting a robust financial position.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will release its financial results for the fourth quarter and full year ended December 31, 2022, after market close on March 28, 2023. A conference call will follow that day at 4:30 p.m. ET. Additionally, Arcturus will present at the Guggenheim Healthcare Talks: Genomic Medicines & Rare Disease Day on April 3, 2023, at 2:10 p.m. ET. Founded in 2013 and based in San Diego, Arcturus focuses on developing mRNA medicines and vaccines for infectious diseases and rare liver and respiratory diseases. The company employs LUNAR® lipid-mediated delivery and STARR™ mRNA Technology to support its diverse pipeline.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced its participation in two upcoming investor conferences. The SVB Securities Global Biopharma Conference will take place on February 15, 2023 at 2:20 p.m. ET, followed by the Barclays Global Healthcare Conference on March 16, 2023 at 9:00 a.m. ET. Arcturus is focused on developing messenger RNA medicines, including vaccines for infectious diseases and therapies for rare liver and respiratory diseases. Additional details and webcast links are available on their website.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced the approval of its Clinical Trial Application (CTA) for ARCT-032, an inhaled mRNA treatment for cystic fibrosis (CF). This marks the progression into Phase 1 First-in-Human studies in New Zealand. Joseph Payne, CEO, emphasized the potential of ARCT-032 to restore CFTR protein in CF patients, including those without effective treatment options. Preclinical data showcased robust CFTR expression in human bronchial epithelial cells. Cystic fibrosis, a serious genetic disorder, currently lacks effective treatments for many mutation types, making this development particularly significant.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced its participation in the Annual J.P. Morgan Healthcare Conference in San Francisco on January 11, 2023, at 9:00 a.m. Pacific Time. The company, known for its mRNA medicines and vaccines, will discuss its pipeline focused on vaccines for infectious diseases and treatments for rare liver and respiratory diseases. A webcast of the presentation will be available on the company's investor relations website.
Founded in 2013, Arcturus continues to innovate in RNA therapeutics with extensive patent coverage.
Arcturus Therapeutics, a late-stage clinical mRNA medicines company, has appointed John Markels, Ph.D., to its Board of Directors. With over 35 years of industry experience, including as President of Global Vaccines at Merck, Dr. Markels will provide strategic oversight for the company's vaccine franchise and manufacturing processes. This appointment is expected to enhance Arcturus' efforts in developing novel self-amplifying mRNA vaccines in collaboration with CSL Seqirus, positioning the company for greater innovation in infectious disease vaccines.
Arcturus Therapeutics (Nasdaq: ARCT) announced a global partnership with CSL for developing self-amplifying mRNA vaccines, securing $200 million upfront and up to $4.3 billion in potential milestones. BARDA awarded $63.2 million for mRNA vaccine development targeting pandemic influenza. Recent data show the effectiveness of ARCT-032 in restoring chloride ion current in cystic fibrosis patients. For Q3 2022, Arcturus reported revenues of $13.4 million, a substantial increase from $2.4 million in Q3 2021, but a net loss of $35.3 million. Cash reserves stood at $237.7 million as of September 30, 2022.